SEARCH

SEARCH BY CITATION

References

  • Asuni A. A., Boutajangout A., Scholtzova H., Knudsen E., Li Y. S., Quartermain D., Frangione B., Wisniewski T. and Sigurdsson E. M. (2006) Vaccination of Alzheimer’s model mice with Aβ derivative in alum adjuvant reduces Aβ burden without microhemorrhages. Eur. J. Neurosci. 24, 25302542.
  • Asuni A. A., Boutajangout A., Quartermain D. and Sigurdsson E. M. (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 27, 91159129.
  • Bacskai B. J., Kajdasz S. T., McLellan M. E., Games D., Seubert P., Schenk D. and Hyman B. T. (2002) Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J. Neurosci. 22, 78737878.
  • Bard F., Cannon C., Barbour R. et al. (2000) Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916919.
  • Bendiske J. and Bahr B. A. (2003) Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis – An approach for slowing Alzheimer disease? J. Neuropathol. Exp. Neurol. 62, 451463.
  • Berger Z., Ravikumar B., Menzies F. M. et al. (2006) Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 15, 433442.
  • Boimel M., Grigoriadis N., Lourbopoulos A., Haber E., Abramsky O. and Rosenmann H. (2010) Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp. Neurol. 224, 472485.
  • Boutajangout A., Leroy K., Touchet N., Authelet M., Blanchard V., Tremp G., Pradier L. and Brion J. P. (2002) Increased tau phosphorylation but absence of formation of neurofibrillary tangles in mice double transgenic for human tau and Alzheimer mutant (M146L) presenilin-1. Neurosci. Lett. 318, 2933.
  • Boutajangout A., Authelet M., Blanchard V., Touchet N., Tremp G., Pradier L. and Brion J. P. (2004) Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer’s disease mutants of APP and presenilin-1. Neurobiol. Dis. 15, 4760.
  • Boutajangout A., Ingadottir J., Davies P. and Sigurdsson E. M. (2010a) Passive tau immunotherapy diminishes functional decline and clears tau aggregates in a mouse model of tauopathy. Alzheimers & Dement. 6, S578.
  • Boutajangout A., Quartermain D. and Sigurdsson E. M. (2010b) Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J. Neurosci. 30, 1655916566.
  • Brion J. P., Hanger D. P., Bruce M. T., Couck A. M., Flamentdurand J. and Anderton B. H. (1991) Tau in Alzheimer neurofibrillary tangles – N-terminal and C-terminal regions are differentially associated with paired helical filaments and the location of a putative abnormal phosphorylation site. Biochem. J. 273, 127133.
  • Clavaguera F., Bolmont T., Crowther R. A. et al. (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11, 909913.
  • Das P., Howard V., Loosbrock N., Dickson D., Murphy M. P. and Golde T. E. (2003) Amyloid-β immunization effectively reduces amyloid deposition in FcRγ-/- knock-out mice. J. Neurosci. 23, 85328538.
  • DeMattos R. B., Bales K. R., Cummins D. J., Dodart J. C., Paul S. M. and Holtzman D. M. (2001) Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA 98, 88508855.
  • Dodart J. C., Meziane H., Mathis C., Bales K. R., Paul S. M. and Ungerer A. (1999) Behavioral disturbances in transgenic mice overexpressing the V717F β-amyloid precursor protein. Behav. Neurosci. 113, 982990.
  • Ferrer I., Boada R. M., Sanchez Guerra M. L., Rey M. J. and Costa-Jussa F. (2004) Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer’s disease. Brain Pathol. 14, 1120.
  • Fisher Y., Nemirovsky A., Baron R. and Monsonego A. (2010) T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer’s disease. PLoS One 5, e10830.
  • Frost B., Jacks R. L. and Diamond M. I. (2009) Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284, 1284512852.
  • Gilman S., Koller M., Black R. S. et al. (2005) Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 15531562.
  • Greenberg S. G. and Davies P. (1990) A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc. Natl. Acad. Sci. USA 87, 58275831.
  • Greenberg S. G., Davies P., Schein J. D. and Binder L. I. (1992) Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J. Biol. Chem. 267, 564569.
  • Hamano T., Gendron T. F., Causevic E., Yen S. H., Lin W. L., Isidoro C., DeTure M. and Ko L. W. (2008) Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur. J. Neurosci. 27, 11191130.
  • Hock C., Konietzko U., Streffer J. R. et al. (2003) Antibodies against β-amyloid slow cognitive decline in Alzheimer’s disease. Neuron. 38, 547554.
  • Holmes C., Boche D., Wilkinson D. et al. (2008) Long-term effects of Aβ(42) immunisation in Alzheimer’s disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216223.
  • Ikeda K., Akiyama H., Arai T., Kondo H., Haga C., Iritani S. and Tsuchiya K. (1998) Alz-50/Gallyas-positive lysosome-like intraneuronal granules in Alzheimer’s disease and control brains. Neurosci. Lett. 258, 113116.
  • Janus C., Pearson J., McLaurin J. et al. (2000) Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 408, 979982.
  • Keizer R. J., Huitema A. D., Schellens J. H. and Beijnen J. H. (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet. 49, 493507.
  • Kotilinek L. A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B. T., Younkin S. and Ashe K. H. (2002) Reversible memory loss in a mouse transgenic model of Alzheimer’s disease. J. Neurosci. 22, 63316335.
  • Krishnamurthy P. K., Deng Y., Mathews P. M. and Sigurdsson E. M. (2010) Mechanistic studies of antibody mediated clearance of tau aggregates using an ex vivo brain slice model. Alzheimers & Dement. 6, S276.
  • Lemere C. A., Spooner E. T., LaFrancois J. et al. (2003) Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice. Neurobiol. Dis. 14, 1018.
  • Lewis J., McGowan E., Rockwood J. et al. (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25, 402405.
  • Lim F., Hernandez F., Lucas J. J., Gomez-Ramos P., Moran M. A. and Avila J. (2001) FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and tau filaments in forebrain. Mol. Cell. Neurosci. 18, 702714.
  • Lin W. L., Lewis J., Yen S. H., Hutton M. and Dickson D. W. (2003) Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau. J. Neurocytol. 32, 10911105.
  • Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L. and Schenk D. (2005a) Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129131.
  • Masliah E., Rockenstein E., Adame A. et al. (2005b) Effects of α-synuclein immunization in a mouse model of Parkinson’s disease. Neuron. 46, 857868.
  • Meeker M. L., Meeker R. B. and Hayward J. N. (1987) Accumulation of circulating endogenous and exogenous immunoglobulins by hypothalamic magnocellular neurons. Brain Res. 423, 4555.
  • Morgan D., Diamond D. M., Gottschall P. E. et al. (2000) Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 408, 982985.
  • Nicoll J. A., Wilkinson D., Holmes C., Steart P., Markham H. and Weller R. O. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med. 9, 448452.
  • Nicoll J. A., Barton E., Boche D. et al. (2006) Aβ species removal after Aβ42 immunization. J. Neuropathol. Exp. Neurol. 65, 10401048.
  • Nixon R. A. (2007) Autophagy, amyloidogenesis and Alzheimer disease. J. Cell Sci. 120, 40814091.
  • Orgogozo J. M., Gilman S., Dartigues J. F. et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61, 4654.
  • Otvos L. Jr, Feiner L., Lang E., Szendrei G. I., Goedert M. and Lee V. M. (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J. Neurosci. Res. 39, 669673.
  • Schenk D. (2002) Amyloid-β immunotherapy for Alzheimer’s disease: the end of the beginning. Nat. Rev. Neurosci. 3, 824828.
  • Schenk D., Barbour R., Dunn W. et al. (1999) Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173177.
  • Schwartz M. and Shechter R. (2010) Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev. Neurol. 6, 405410.
  • Sigurdsson E. M. (2006) Immunotherapy for conformational diseases. Curr. Pharm. Des. 12, 25692585.
  • Sigurdsson E. M. (2009) Tau-focused immunotherapy for Alzheimer’s disease and related tauopathies. Curr. Alzheimer Res. 6, 446450.
  • Sigurdsson E. M., Lorens S. A., Hejna M. J., Dong X. W. and Lee J. M. (1996) Local and distant histopathological effects of unilateral amyloid-β 25–35 injections into the amygdala of young F344 rats. Neurobiol. Aging 17, 893901.
  • Sigurdsson E. M., Scholtzova H., Mehta P. D., Frangione B. and Wisniewski T. (2001) Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer’s disease associated pathology in transgenic mice. Am. J. Pathol. 159, 439447.
  • Sigurdsson E., Wisniewski T. and Frangione B. (2002) Infectivity of amyloid diseases. Trends Mol. Med. 8, 411.
  • Sigurdsson E. M., Knudsen E., Asuni A., Fitzer-Attas C., Sage D., Quartermain D., Goni F., Frangione B. and Wisniewski T. (2004) An attenuated immune response is sufficient to enhance cognition in an Alzheimer’s disease mouse model immunized with amyloid-β derivatives. J. Neurosci. 24, 62776282.
  • Solomon B., Koppel R., Frankel D. and Hanan-Aharon E. (1997) Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl Acad. Sci. USA 94, 41094112.
  • Tampellini D., Magrane J., Takahashi R. H., Li F., Lin M. T., Almeida C. G. and Gouras G. K. (2007) Internalized antibodies to the Aβ domain of APP reduce neuronal Aβ and protect against synaptic alterations. J. Biol. Chem. 282, 1889518906.
  • Wang Y., Martinez-Vicente M., Kruger U., Kaushik S., Wong E., Mandelkow E. M., Cuervo A. M. and Mandelkow E. (2009) Tau fragmentation, aggregation and clearance: The dual role of lysosomal processing. Hum. Mol. Genet. 18, 41534170.